306 related articles for article (PubMed ID: 18754846)
1. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study.
Diav-Citrin O; Shechtman S; Weinbaum D; Wajnberg R; Avgil M; Di Gianantonio E; Clementi M; Weber-Schoendorfer C; Schaefer C; Ornoy A
Br J Clin Pharmacol; 2008 Nov; 66(5):695-705. PubMed ID: 18754846
[TBL] [Abstract][Full Text] [Related]
2. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage.
Bérard A; Ramos E; Rey E; Blais L; St-André M; Oraichi D
Birth Defects Res B Dev Reprod Toxicol; 2007 Feb; 80(1):18-27. PubMed ID: 17187388
[TBL] [Abstract][Full Text] [Related]
3. Selective serotonin reuptake inhibitors and risk for major congenital anomalies.
Malm H; Artama M; Gissler M; Ritvanen A
Obstet Gynecol; 2011 Jul; 118(1):111-120. PubMed ID: 21646927
[TBL] [Abstract][Full Text] [Related]
4. Serotonin reuptake inhibitor antidepressants and pregnancy: many unanswered questions.
Prescrire Int; 1999 Oct; 8(43):157-9. PubMed ID: 11503843
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of depressed pregnant women by selective serotonin reuptake inhibitors: risk for the foetus and the newborn].
Favrelière S; Nourrisson A; Jaafari N; Pérault Pochat MC
Encephale; 2010 Jun; 36 Suppl 2():D133-8. PubMed ID: 20513456
[TBL] [Abstract][Full Text] [Related]
6. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine.
Gentile S; Bellantuono C
J Clin Psychiatry; 2009 Mar; 70(3):414-22. PubMed ID: 19254517
[TBL] [Abstract][Full Text] [Related]
7. SSRI antidepressants and birth defects.
Prescrire Int; 2006 Dec; 15(86):222-3. PubMed ID: 17167929
[TBL] [Abstract][Full Text] [Related]
8. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study.
Bakker MK; Kerstjens-Frederikse WS; Buys CH; de Walle HE; de Jong-van den Berg LT
Birth Defects Res A Clin Mol Teratol; 2010 Feb; 88(2):94-100. PubMed ID: 19937603
[TBL] [Abstract][Full Text] [Related]
9. Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors.
Bar-Oz B; Einarson T; Einarson A; Boskovic R; O'Brien L; Malm H; Bérard A; Koren G
Clin Ther; 2007 May; 29(5):918-926. PubMed ID: 17697910
[TBL] [Abstract][Full Text] [Related]
10. The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis.
Bérard A; Iessa N; Chaabane S; Muanda FT; Boukhris T; Zhao JP
Br J Clin Pharmacol; 2016 Apr; 81(4):589-604. PubMed ID: 26613360
[TBL] [Abstract][Full Text] [Related]
11. Selective serotonin reuptake inhibitor antidepressant use in first trimester pregnancy and risk of specific congenital anomalies: a European register-based study.
Wemakor A; Casson K; Garne E; Bakker M; Addor MC; Arriola L; Gatt M; Khoshnood B; Klungsoyr K; Nelen V; O'Mahoney M; Pierini A; Rissmann A; Tucker D; Boyle B; de Jong-van den Berg L; Dolk H
Eur J Epidemiol; 2015 Nov; 30(11):1187-98. PubMed ID: 26148560
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment.
Judge R; Parry MG; Quail D; Jacobson JG
Int Clin Psychopharmacol; 2002 Sep; 17(5):217-25. PubMed ID: 12177584
[TBL] [Abstract][Full Text] [Related]
13. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study.
Kulin NA; Pastuszak A; Sage SR; Schick-Boschetto B; Spivey G; Feldkamp M; Ormond K; Matsui D; Stein-Schechman AK; Cook L; Brochu J; Rieder M; Koren G
JAMA; 1998 Feb; 279(8):609-10. PubMed ID: 9486756
[TBL] [Abstract][Full Text] [Related]
14. Effects of first-trimester fluoxetine exposure on the newborn.
Goldstein DJ; Corbin LA; Sundell KL
Obstet Gynecol; 1997 May; 89(5 Pt 1):713-8. PubMed ID: 9166307
[TBL] [Abstract][Full Text] [Related]
15. Use of selective serotonin reuptake inhibitors during pregnancy and risk of major and cardiovascular malformations: an update.
Tuccori M; Montagnani S; Testi A; Ruggiero E; Mantarro S; Scollo C; Pergola A; Fornai M; Antonioli L; Colucci R; Corona T; Blandizzi C
Postgrad Med; 2010 Jul; 122(4):49-65. PubMed ID: 20675971
[TBL] [Abstract][Full Text] [Related]
16. Fluoxetine and infantile hypertrophic pylorus stenosis: a signal from a birth defects-drug exposure surveillance study.
Bakker MK; De Walle HE; Wilffert B; de Jong-Van den Berg LT
Pharmacoepidemiol Drug Saf; 2010 Aug; 19(8):808-13. PubMed ID: 20572024
[TBL] [Abstract][Full Text] [Related]
17. Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation.
Bogetto F; Bellino S; Revello RB; Patria L
CNS Drugs; 2002; 16(4):273-83. PubMed ID: 11945110
[TBL] [Abstract][Full Text] [Related]
18. An imperfect literature and evidence-based medicine.
Freeman MP
J Clin Psychiatry; 2009 Mar; 70(3):412-3. PubMed ID: 19317958
[No Abstract] [Full Text] [Related]
19. Remission of SSRI-induced akathisia after switch to nefazodone.
Chelben J; Strous RD; Lustig M; Baruch Y
J Clin Psychiatry; 2001 Jul; 62(7):570-1. PubMed ID: 11488371
[No Abstract] [Full Text] [Related]
20. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies.
Wurst KE; Poole C; Ephross SA; Olshan AF
Birth Defects Res A Clin Mol Teratol; 2010 Mar; 88(3):159-70. PubMed ID: 19739149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
